Are you Dr. Bahceci?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Yale Physicians Building
New Haven, CT 06519Phone+1 203-785-2140Fax+1 203-785-6414
Summary
- Dr. Erkut Bahceci, MD is a hematologist in New Haven, Connecticut. He is currently licensed to practice medicine in Virginia.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Loyola University Medical Center/Trinity-Mercy ChicagoResidency, Internal Medicine, 1993 - 1996
Marmara Univ- Fac MedClass of 1990
Certifications & Licensure
VA State Medical License 2011 - 2026
Clinical Trials
Publications & Presentations
PubMed
- 355 citationsSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyAlexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow
The Lancet. Oncology. 2017-08-01 - 49 citationsGilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutationsTheodore C. Tarver, Jason E. Hill, Leena T. Rahmat, Alexander E. Perl, Erkut Bahceci
Blood Advances. 2020-02-11 - 28 citationsMolecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Catherine C Smith, Mark J Levis, Alexander E Perl, Jason E Hill, Matt Rosales
Blood Advances. 2022-04-12
Press Mentions
BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical OfficerJanuary 30th, 2023- BlueSphere Bio Announces IND Clearance of Its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia PatientsJune 18th, 2024
